Clinical Trial

CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER)

Study acronym: KOV-HIPEC-02R
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 12, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Platinum-resistant recurrent epithelial ovarian cancer randomizing with or without cytoreductive surgery + hyperthermic intraperitoneal chemotherapy (HIPEC): KOV-02R, RECOVER
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-03-30; most recent amendment 2026-02-11.
Status change: Recruiting → Active, Not Recruiting 2026-02-11
Status change: Not Yet Recruiting → Recruiting 2022-04-07
Trial Details
NCT Number NCT05316181
Lead Sponsor National Cancer Center, Korea
Conditions Epithelial Ovarian Cancer, Platinum Resistant, Recurrent Ovarian, HIPEC, Mitomycin, Cytoreductive Surgery
Enrollment 140 participants
Start Date 2022-04-07
Primary Completion 2026-06-30 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-12